In order to better provide you with products and services offered on our Site, Noga Therapeutics may collect personally identifiable information, such as your:
Please keep in mind that if you directly disclose personally identifiable information or personally sensitive data through Noga Therapeutics’s public message boards, this information may be collected and used by others.
We do not collect any personal information about you unless you voluntarily provide it to us or is provided to us by an agent authorized by you. However, you may be required to provide certain personal information to us when you elect to use certain products or services available on the Site. These may include: (a) registering for an account on our Site; (b) entering a sweepstakes or contest sponsored by us or one of our partners; (c) signing up for special offers from selected third parties; (d) sending us an email message; (e) submitting your credit card or other payment information when ordering and purchasing products and services on our Site. To wit, we will use your information for, but not limited to, communicating with you in relation to services and/or products you have requested from us. We also may gather additional personal or non-personal information in the future.
Noga Therapeutics collects and uses your personal information to operate its website(s) and deliver the services you have requested.
Noga Therapeutics may also use your personally identifiable information to inform you of other products or services available from Noga Therapeutics and its affiliates.
Noga Therapeutics does not sell, rent or lease its customer lists to third parties.
Noga Therapeutics may share data with trusted partners to help perform statistical analysis, send you email or postal mail, provide customer support, or arrange for deliveries. All such third parties are prohibited from using your personal information except to provide these services to Noga Therapeutics, and they are required to maintain the confidentiality of your information.
Noga Therapeutics may disclose your personal information, without notice, if required to do so by law or in the good faith belief that such action is necessary to: (a) conform to the edicts of the law or comply with legal process served on Noga Therapeutics or the site; (b) protect and defend the rights or property of Noga Therapeutics; and/or (c) act under exigent circumstances to protect the personal safety of users of Noga Therapeutics, or the public.
Information about your computer hardware and software may be automatically collected by Noga Therapeutics. This information can include: your IP address, browser type, domain names, access times and referring website addresses. This information is used for the operation of the service, to maintain quality of the service, and to provide general statistics regarding use of the Noga Therapeutics website.
The Noga Therapeutics website may use “cookies” to help you personalize your online experience. A cookie is a text file that is placed on your hard disk by a web page server. Cookies cannot be used to run programs or deliver viruses to your computer. Cookies are uniquely assigned to you, and can only be read by a web server in the domain that issued the cookie to you.
One of the primary purposes of cookies is to provide a convenience feature to save you time. The purpose of a cookie is to tell the Web server that you have returned to a specific page. For example, if you personalize Noga Therapeutics pages, or register with Noga Therapeutics site or services, a cookie helps Noga Therapeutics to recall your specific information on subsequent visits. This simplifies the process of recording your personal information, such as billing addresses, shipping addresses, and so on. When you return to the same Noga Therapeutics website, the information you previously provided can be retrieved, so you can easily use the Noga Therapeutics features that you customized.
You have the ability to accept or decline cookies. Most Web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies if you prefer. If you choose to decline cookies, you may not be able to fully experience the interactive features of the Noga Therapeutics services or websites you visit.
This website contains links to other sites. Please be aware that we are not responsible for the content or privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of any other site that collects personally identifiable information.
Noga Therapeutics secures your personal information from unauthorized access, use, or disclosure. Noga Therapeutics uses the following methods for this purpose:
When personal information (such as a credit card number) is transmitted to other websites, it is protected through the use of encryption, such as the Secure Sockets Layer (SSL) protocol.
We strive to take appropriate security measures to protect against unauthorized access to or alteration of your personal information. Unfortunately, no data transmission over the Internet or any wireless network can be guaranteed to be 100% secure. As a result, while we strive to protect your personal information, you acknowledge that: (a) there are security and privacy limitations inherent to the Internet which are beyond our control; and (b) security, integrity, and privacy of any and all information and data exchanged between you and us through this Site cannot be guaranteed.
Subject to certain exceptions set out below, on receipt of a verifiable request from you, we will:
In certain instances, if your information was provided to us through an intermediary, we may additional verification prior to taking actions towards deleting your information.
Please note that we may not be able to comply with requests to delete your personal information if it is necessary to:
Noga Therapeutics does not knowingly collect personally identifiable information from children under the age of thirteen. If you are under the age of thirteen, you must ask your parent or guardian for permission to use this website.
From time to time, Noga Therapeutics may contact you via email for the purpose of providing announcements, promotional offers, alerts, confirmations, surveys, and/or other general communication. In order to improve our Services, we may receive a notification when you open an email from Noga Therapeutics or click on a link therein.
If you would like to stop receiving marketing or promotional communications via email from Noga Therapeutics, you may opt out of such communications by Customers may unsubscribe from emails by “replying STOP” or clicking on the UNSUBSCRIBE button.
We may store your data on servers provided by third party hosting vendors with whom we have contracted.
Noga Therapeutics welcomes your questions or comments regarding this Statement of Privacy. If you believe that Noga Therapeutics has not adhered to this Statement, please contact Noga Therapeutics at:
3 Pinchas Sapir St
Ness Ziona, 7403626, Israel
Effective as of March 28, 2023
Sefi is a 22-year entrepreneur who founded a Nasdaq-listed company. He has a proven track record of assembling exceptional teams and building technology ahead of its time.
Sefi founded HUB Cyber Security, which reached a peak market capitalization of $350 million. He also advised Bancor, which raised $153 million and reached a peak market capitalization of $800 million.
Currently Sefi is heading the investment team in a privately owned family office.
Sefi holds a B.Sc. in Business Administration and Economics from the University of Tel Aviv.
Mr. Adam Brian heads Lonza Personalized Medicine, which focuses on developing and bringing to market tools that enable research and development, scale out, and commercialization of patient scale cell therapies, with an emphasis on decentralized and point of care manufacturing. Mr. Brian is a results-oriented leader with extensive experience in the life science and medical device industries. Proven track record of increasing revenue, improving operations, and building and leading high-performing teams.
Dr. Eytan Abraham heads Resilience cell, gene and nucleic acids Franchises. Dr. Abraham holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell-therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School. Dr. Abraham is an experienced scientist and business leader with expertise in basic and applied biological and cell therapy R&D as well as in management, technology, and commercialization.
Anat Naschitz is a lifescience investor and entrepreneur, with 27 years of experience across biotech, pharma, digital health and medical devices.
Anat co-founded and co-led OrbiMed Israel, an Israel focused VC fund and part of the leading, $20bn global healthcare investment firm, and was previously with Apax, the €60bn private equity firm, where she started her investment career. Previously Anat was an Associate Partner with McKinsey in London, where she advised the world’s preeminent pharmaceutical companies on strategy, acquisitions and spinouts.
Throughout her career Anat has founded companies and nurtured them through success. Examples include 89bio (Nasdaq:ETNB), developing a likely best in class therapeutic for NASH, which she co-founded and spun out of Teva, taking it public on Nasdaq 18 months post creation, currently trading at $1bn; Sobi, which evolved out of a Pharmacia spinout and currently trading at $7.4bn; and many others.
Currently, Anat is co-founder and CEO of 9xchange, a biopharma marketplace, creating transparency and enabling the ecosystem to monetize pipelines and discover assets whose availability was unknown, through a seamless, initially anonymous, AI-driven process.
Anat earned her MBA at Insead in France and her LLB at Tel Aviv University.
Dr. Yeal Weiss is currently CEO of Mahzi Therapeutics, a company focused on the development of therapies for ultra-rare genetic neurodevelopmental disorders. Dr. Weiss completed her MD at Hadassah Medical School at the Hebrew University in Jerusalem and her PhD at the Weizmann Institute of Science in Rehovot, Israel. She has over 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck and Ultragenyx. Dr. Weiss is a member of the NIH driven Bespoke Gene Therapy (BCTG) consortium, ASGCT translational committee, N=1 collaborative and is a 2022 Termeer Fellow. Board member/advisor to ADNP and FOXG1 foundations.
Noam is a physician with 20 years of experience in the field of complementary medicine (Brighton University). He formerly headed the Chinese Medicine Unit at Sheba Hospital. Noam is the founder and CEO of the Association for Noga (Her Way), which develops advanced therapies for ultra-rare diseases.
Liron brings many years of experience in cell- and gene-therapy translation. Prior to joining NOGA Therapeutics, Liron headed the discovery and the early-phase development of oncology at Enlivex Therapeutics. Prior to that, Liron led the hemophilia A program (currently in phase III) at Spark Therapeutics, USA. Liron holds a PhD from and conducted postdoctoral research at the Technion.
Noam previously co-founded Emendo Biotherapeutics, a leading CRISPR company that was acquired by Anges, Japan, in 2020, for $295M. As an expert on intellectual property strategies at Ingenium IP, Noam advised dozens of biomed companies on building their IP-business strategy. Noam holds a PhD from the Weizmann Institute of Science in the field of DNA damage repair.